Navigation Links
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
Date:10/9/2007

- Now for Exclusion of Venous Thromboembolism -

LEXINGTON, Mass., Oct. 9 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance to expand the intended use for HemosIL D-Dimer HS to exclude venous thromboembolism (VTE) in outpatients suspected of deep vein thrombosis (DVT) and pulmonary embolism (PE), when used in conjunction with a clinical pretest probability assessment model. HemosIL D-Dimer HS was released in 2005 with claims for use as an aid in the diagnosis of VTE.

As part of the 510(k), IL submitted data from a multi-center clinical study conducted at four different hospitals using HemosIL D-Dimer HS on the ACL TOP(R) Hemostasis Testing System with 668 samples from patients admitted consecutively to the emergency department, suspected of having DVT or PE. HemosIL D-Dimer HS safely excluded DVT or PE with a negative predictive value of 100%.

HemosIL D-Dimer HS is the latest generation D-Dimer assay and features expanded working range, high analytical sensitivity, virtually no interference from rheumatoid factor and minimal optical interference from hemoglobin, lipemia and bilirubin. It is fully automated on the ACL TOP system with time to results in less than five minutes.

"This milestone exemplifies IL's focus on robust, reliable and easy-to-use assays with clear indications for use and proven clinical performance for disease-state-management," said Giovanni Russi, Director of Worldwide Marketing, Hemostasis Reagents at IL. "We hope that these new claims for D-Dimer HS will help physicians more accurately and efficiently diagnose patients suspected of VTE."

Instrumentation Laboratory (http://www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM product offerings, part of the critical care line, include the new GEM Premier 4000 analyzer with Intelligent Quality Management (iQM(R)), GEM Premier 3000 analyzer, GEM OPL(TM), a portable whole blood CO-Oximeter and the GEM PCL Plus, a portable Coagulation analyzer. IL's hemostasis portfolio includes the ACL TOP(R), a fully automated, high-productivity analyzer and the ACL ELITE(R), the latest addition to the ACL family. IL also offers the HemosIL(R) line of reagents. IL is based in Lexington, Massachusetts.


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The combination of monolithic columns and modern HPLC/MS/MS instrumentation for high chromatographic throughput and sensitive detection of beta-agonists
2. Setting up the laboratory to avoid contamination
3. Improving the Efficiency of Common Filtration Tasks in your Laboratory
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. E-business conference to give sneak peek into university RFID laboratory
6. Medical College receives $377K to study brain disease
7. Lucigen receives $750K grant to boost biofuel yields
8. Medical College receives $1.4M cancer grant
9. Wisconsin biotech firm receives $107K NIH grant
10. InvivoSciences receives NIH grant for heart technology
11. Medical College receives $11 million grant to study high blood pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Switzerland from December 5-10. ... Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed ...
(Date:12/2/2016)... Conn. , Dec. 2, 2016  The Multiple ... presentations from the MMRF CoMMpass Study SM —the largest ... accelerating precision medicine in multiple myeloma—will be presented at ... Annual Meeting & Exposition in San Diego ... helping to optimize treatment strategies, as well as identify ...
(Date:12/2/2016)... 2, 2016 CytRx Corporation (NASDAQ: ... in oncology, today announced the appointment of Earl ... consultant, and private healthcare investor, to its Board of ... with clinical and strategic experience at the highest level," ... CEO. "As one of the world,s leading orthopedic surgeons, ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):